MBX

MBX Biosciences, Inc. Common Stock

6.04 USD
-0.33
5.18%
At close Apr 4, 4:00 PM EDT
After hours
5.89
-0.15
2.48%
1 day
-5.18%
5 days
-20.21%
1 month
-43.97%
3 months
-62.90%
6 months
-74.57%
Year to date
-66.90%
1 year
-74.46%
5 years
-74.46%
10 years
-74.46%
0
Funds holding %
of 7,398 funds
Analysts bullish %

Fund manager confidence

Based on 2024 Q4 regulatory disclosures by fund managers ($100M+ AUM)

120% more first-time investments, than exits

New positions opened: 33 | Existing positions closed: 15

41% more funds holding

Funds holding: 44 [Q3] → 62 (+18) [Q4]

38% more repeat investments, than reductions

Existing positions increased: 11 | Existing positions reduced: 8

3.4% more ownership

Funds ownership: 95.16% [Q3] → 98.56% (+3.4%) [Q4]

0% more funds holding in top 10

Funds holding in top 10: 3 [Q3] → 3 (+0) [Q4]

23% less capital invested

Capital invested by funds: $783M [Q3] → $606M (-$177M) [Q4]

Research analyst outlook

We haven’t received any recent analyst ratings for MBX.

Financial journalist opinion

Neutral
GlobeNewsWire
1 week ago
MBX Biosciences to Participate in the 24th Annual Needham Virtual Healthcare Conference
CARMEL, Ind., March 26, 2025 (GLOBE NEWSWIRE) -- MBX Biosciences, Inc. (Nasdaq: MBX), a clinical-stage biopharmaceutical company focused on the discovery and development of novel precision peptide therapies for the treatment of endocrine and metabolic disorders, today announced that Kent Hawryluk, President and Chief Executive Officer, will present at and participate in the 24th Annual Needham Virtual Healthcare Conference.
MBX Biosciences to Participate in the 24th Annual Needham Virtual Healthcare Conference
Neutral
GlobeNewsWire
2 weeks ago
MBX Biosciences Reports Fourth Quarter and Full Year 2024 Financial Results and Recent Corporate Highlights
Enrollment complete in Phase 2 Avail™ trial of canvuparatide in hypoparathyroidism; topline results on track for Q3 2025 MBX 1416 Phase 2 trial in patients with post-bariatric hypoglycemia expected to begin in 2H 2025 Investigational New Drug submission anticipated in Q2 2025 for MBX 4291 in obesity $262.1 million in cash, cash equivalents and marketable securities as of December 31, 2024; expected to support operations into mid-2027 CARMEL, Ind., March 17, 2025 (GLOBE NEWSWIRE) -- MBX Biosciences, Inc. (Nasdaq: MBX), a clinical-stage biopharmaceutical company focused on the discovery and development of novel precision peptide therapies for the treatment of endocrine and metabolic disorders, today reported financial results for the fourth quarter and full year ended December 31, 2024, and highlighted recent corporate progress.
MBX Biosciences Reports Fourth Quarter and Full Year 2024 Financial Results and Recent Corporate Highlights
Neutral
GlobeNewsWire
1 month ago
MBX Biosciences Announces Additions to Leadership Team
Chatan Charan, Ph.D. appointed as Senior Vice President, Pharmaceutical Development and CMC Mark Hope appointed as Senior Vice President, Regulatory and Quality CARMEL, Ind.
MBX Biosciences Announces Additions to Leadership Team
Neutral
GlobeNewsWire
1 month ago
MBX Biosciences Completes Enrollment in Phase 2 Avail™ Trial of MBX 2109 (Canvuparatide) for Hypoparathyroidism
CARMEL, Ind., March 03, 2025 (GLOBE NEWSWIRE) -- MBX Biosciences, Inc. (Nasdaq: MBX), a clinical-stage biopharmaceutical company focused on the discovery and development of novel precision peptide therapies for the treatment of endocrine and metabolic disorders, today announced the completion of enrollment in its Phase 2 Avail™ trial of MBX 2109 (canvuparatide), the Company's parathyroid hormone (PTH) peptide prodrug.
MBX Biosciences Completes Enrollment in Phase 2 Avail™ Trial of MBX 2109 (Canvuparatide) for Hypoparathyroidism
Neutral
GlobeNewsWire
1 month ago
MBX Biosciences to Participate in March Investor Conferences
CARMEL, Ind., Feb. 18, 2025 (GLOBE NEWSWIRE) -- MBX Biosciences, Inc. (Nasdaq: MBX), a clinical-stage biopharmaceutical company focused on the discovery and development of novel precision peptide therapies for the treatment of endocrine and metabolic disorders, today announced that Kent Hawryluk, President and Chief Executive Officer, will present at and participate in the following investor conferences: TD Cowen 45th Annual Healthcare Conference Date: Monday, March 3, 2025Format: Podium Presentation and 1x1 meetingsTime: 10:30 a.m.
MBX Biosciences to Participate in March Investor Conferences
Neutral
GlobeNewsWire
2 months ago
MBX Biosciences Announces Positive Phase 1 Topline Results for MBX 1416 for the Treatment of Post-bariatric Hypoglycemia
Phase 1 results support proceeding to Phase 2 in patients with post-bariatric hypoglycemia (PBH) , which is expected to begin in 2H 2025
MBX Biosciences Announces Positive Phase 1 Topline Results for MBX 1416 for the Treatment of Post-bariatric Hypoglycemia
Neutral
GlobeNewsWire
4 months ago
MBX Biosciences Announces Last Subject Last Visit in Phase 1 Trial of MBX 1416 for the Treatment of Post-Bariatric Hypoglycemia
CARMEL, Ind., Nov. 18, 2024 (GLOBE NEWSWIRE) -- MBX Biosciences, Inc. (Nasdaq: MBX), a clinical-stage biopharmaceutical company focused on the discovery and development of novel precision peptide therapies for the treatment of endocrine and metabolic disorders, today announced the completion of the last subject's last visit in its Phase 1 single and multiple ascending dose trial of MBX 1416, the Company's long-acting glucagon-like peptide 1 (GLP-1) receptor antagonist in development for the treatment of post-bariatric hypoglycemia (PBH).
MBX Biosciences Announces Last Subject Last Visit in Phase 1 Trial of MBX 1416 for the Treatment of Post-Bariatric Hypoglycemia
Neutral
GlobeNewsWire
5 months ago
MBX Biosciences to Participate in Upcoming November Investor Conferences
CARMEL, Ind., Oct. 28, 2024 (GLOBE NEWSWIRE) -- MBX Biosciences, Inc. (NASDAQ: MBX), a clinical-stage biopharmaceutical company focused on the discovery and development of novel precision peptide therapies for the treatment of endocrine and metabolic disorders, today announced that its management team will participate in the following upcoming investor conferences:
MBX Biosciences to Participate in Upcoming November Investor Conferences
Neutral
GlobeNewsWire
6 months ago
MBX Biosciences Presents MBX 2109 Phase 2 Avail™ Hypoparathyroidism Trial Rationale and Design at the ASBMR 2024 Annual Meeting
CARMEL, Ind., Sept. 30, 2024 (GLOBE NEWSWIRE) -- MBX Biosciences, Inc. (NASDAQ: MBX), a clinical-stage biopharmaceutical company focused on the discovery and development of novel precision peptide therapies for the treatment of endocrine and metabolic disorders, today announced that both the rationale and design of the Phase 2 Avail™ trial of MBX 2109, the Company's potential long-acting parathyroid hormone (PTH) peptide prodrug, in adults with hypoparathyroidism (HP) were featured in a poster presentation at the American Society for Bone and Mineral Research (ASBMR) 2024 Annual Meeting held in Toronto, ON, Canada September 27-30, 2024.
MBX Biosciences Presents MBX 2109 Phase 2 Avail™ Hypoparathyroidism Trial Rationale and Design at the ASBMR 2024 Annual Meeting
Neutral
24/7 Wall Street
6 months ago
Last Week's 3 Biotech IPOs Prompt Huge Insider Buying
24/7 Wall St. Insights Initial public offerings at three biotechs last week tempted insiders to make huge purchases of shares.
Last Week's 3 Biotech IPOs Prompt Huge Insider Buying
Charts implemented using Lightweight Charts™